Next-Generation Bruton Tyrosine Kinase Inhibitors

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. May 27, 2020 ARTICLE CITATION DOI: 10.1200/JCO.20.01594 Journal of Clinical Oncology - published online before print July 16, 2020 PMID: 32673168 Next-Generation Bruton Tyrosine Kinase Inhibitors Deborah M. Stephens, DO1xDeborah M. StephensSearch for articles by this author and John C. Byrd, MD2xJohn C. ByrdSearch for articles by this author Show More 1University of Utah, Salt Lake City, UT2The Ohio State University, Columbus, OH https://doi.org/10.1200/JCO.20.01594 First Page Full Text PDF Figures and Tables © 2020 by American Society of Clinical Oncology Companion ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia